Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 75%
filed 2026-08-06
EX-99.1
This is an announcement of the Company's intention to report second quarter 2026 financial results on August 20, 2026, with details of a conference call. While the actual results are not disclosed in this exhibit, the announcement of an upcoming earnings report and conference call is a standard precursor to an earnings release event. The disclosure would be material to investors as it signals the timing of material financial results disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
FS KKR Capital Corp disclosed Q2 2026 financial results (quarter ended June 30, 2026) including net investment income of $0.44 per share, net asset value of $18.30 per share, and earnings per share of ($0.13), along with portfolio highlights and leverage metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Howmet Aerospace issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, including revenue of $2.547 billion (up 24% YoY), GAAP EPS of $1.33 (up 33% YoY), and adjusted EPS of $1.33 (up 46% YoY). The press release is attached as Exhibit 99.1 and constitutes a standard earnings disclosure under Item 2.02, with material financial metrics exceeding guidance and full-year guidance increased.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Iovance Biotherapeutics. The filing explicitly states "issued a press release announcing its financial results for the second quarter ended June 30, 2026" under Item 2.02. The press release reports record revenue of ~$99M (up 66% YoY), gross margin of 56%, and includes business achievements and corporate updates. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Resolute Holdings' financial results for Q2 2026 and the six-month period ended June 30, 2026. The press release reports quarterly EPS of $(1.53) versus $(0.07) in the prior year, Non-GAAP Fee-Related Earnings per share of $0.69 versus $0.08, and includes detailed consolidated financial statements (balance sheet, income statement, and cash flows). The filing explicitly states the press release is attached as Exhibit 99.1 and Item 2.02 is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Ironwood Pharmaceuticals disclosed Q2 2026 financial results with total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, along with raised full-year 2026 guidance for U.S. LINZESS net sales ($1.15–$1.20 billion), total revenue ($460–$485 million), and adjusted EBITDA (>$310 million).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Aclaris Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing includes condensed consolidated statements of operations showing net loss of $21.5 million for Q2 2026 and $41.3 million for the six-month period, along with balance sheet and cash flow data. The press release (Exhibit 99.1) announces these quarterly and year-to-date financial results, which is the hallmark of an earnings_release event under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Cogent Communications' Q2 2026 financial results. The Item 2.02 section explicitly states that "Cogent Communications Holdings, Inc. issued a press release summarizing its financial results for the second quarter of 2026" and the press release (Exhibit 99.1) provides comprehensive quarterly financial data including service revenue ($235.6 million), EBITDA, gross profit, earnings per share ($1.39), and detailed operational metrics. This is the standard form of quarterly earnings disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The press release discloses quarterly financial results including net income ($26.0 million), diluted EPS ($0.14), RevPAR metrics, Adjusted EBITDAre ($76.7 million), and Adjusted FFO per share ($0.32), along with updated full-year 2026 guidance. The filing is structured as Item 2.02 with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses key financial metrics including revenue of $274.3M (5% YoY growth), volume of $23.7B (15% YoY growth), and operational highlights. While the filing also mentions the pending Nuvei acquisition, the primary disclosure under Item 2.02 is the quarterly financial results announcement, which is material to investors assessing the company's operational performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-08-06
EX-99.1
This is an announcement of an upcoming earnings release for Q2 2026 (unaudited financial results for the quarter ended June 30, 2026) scheduled for August 20, 2026. While the actual results are not disclosed in this exhibit, the announcement itself constitutes a material disclosure of the timing and logistics for the earnings announcement, which is a standard material event for public companies. The exhibit includes conference call details and webcast information for investors to access the results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Item 2.02 discloses Edgewise's second quarter 2026 financial results via press release, including R&D expenses ($47.5M), G&A expenses ($14.4M), and net loss ($57.3M or $0.53 per share). The filing explicitly states "Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the full press release attached as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Ocugen issued a press release on August 6, 2026, announcing second quarter 2026 financial results, including cash position ($100.4M as of June 30, 2026), operating expenses ($17.9M for Q2 2026), and net loss per share ($0.07). The filing explicitly states the Company "reported second quarter 2026 financial results" and includes condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
CION Investment Corporation reported second quarter 2026 financial results, including net investment income of $0.29 per share, earnings per share of $0.62, and net asset value per share of $13.57, along with detailed portfolio and operational metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
The 8-K discloses Axcelis Technologies' financial results for Q2 2026 (quarter ended June 30, 2026) via a press release attached as Exhibit 99.1. Item 2.02 explicitly states the company "issued a press release regarding its financial results for its quarter ended June 30, 2026," with revenue of $215.2 million, GAAP diluted EPS of $0.75, and non-GAAP diluted EPS of $1.06. This is a standard quarterly earnings release material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
International Bancshares Corporation issued a news release on August 6, 2026, announcing net income for the three and six months ended June 30, 2026. The release discloses quarterly and year-to-date financial results including net income ($198.0 million for six months, $95.8 million for Q2), diluted earnings per share ($3.18 and $1.54 respectively), and balance sheet metrics (total assets, loans, deposits). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Trinseo's second quarter and six-month financial results for the period ended June 30, 2026. The press release (Exhibit 99.1) presents net sales of $845 million for Q2 2026, net loss of $120 million, diluted EPS of $(3.27), and detailed segment performance. The filing explicitly states the Company "issued a press release announcing its financial results for the second quarter and year ended June 30, 2026," which is the hallmark of an earnings_release event under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
AerSale issued a press release on August 6, 2026 announcing its financial results for the fiscal quarter ended June 30, 2026, disclosing revenue of $70.9 million (down 33.9% YoY), a net loss of $5.6 million (versus net income of $8.6 million in Q2 2025), and adjusted EBITDA of $2.2 million (down 87.9% YoY). The filing explicitly states the press release is furnished as Exhibit 99.1 and includes detailed financial statements and segment performance data, which is the standard format for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a straightforward earnings release disclosing Rigetti's financial results for Q2 2026 (three and six months ended June 30, 2026). The press release, furnished as Exhibit 99.1, reports total revenues of $5.1 million, operating loss of $28.1 million, GAAP net loss of $52.6 million, and cash position of $541.3 million as of June 30, 2026. Item 2.02 explicitly covers "Results of Operations and Financial Condition," and the disclosure includes both financial highlights and business updates typical of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Texas Roadhouse disclosed financial results for the 13 and 26 weeks ended June 30, 2026, including comparable restaurant sales growth of 6.2% and 6.7% respectively, net income, diluted EPS, and 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
MetaVia issued a press release on August 6, 2026, announcing financial results for Q2 2026 ended June 30, 2026, including a net loss of $5.3 million ($0.90 per share), R&D expenses of $3.5 million, G&A expenses of $1.9 million, and a cash position of $12.6 million, along with clinical development milestones.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states "Westrock Coffee Company (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the earnings press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, segment results, and forward guidance, which are hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Astrana Health issued a press release on August 6, 2026 announcing financial results for Q2 2026 and the six months ended June 30, 2026, reporting revenue of $972.5 million (up 49% YoY), net income of $18.5 million (up 81% YoY), and adjusted EBITDA of $68.9 million (up 43% YoY), along with updated 2026 guidance. A conference call and earnings presentation were furnished to discuss the results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
RE/MAX Holdings issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $68.5 million, net loss of $4.3 million, and Adjusted EBITDA of $22.9 million. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Conditions), with the full text furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
CVRx issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing revenue of $15.7 million (16% growth), gross margin of 87%, net loss of $14.0 million, and updated full-year 2026 guidance. The filing explicitly states the press release is attached as Exhibit 99.1 and incorporated by reference under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Structure Therapeutics issued a press release on August 6, 2026 providing financial results for the second quarter ended June 30, 2026, including R&D expenses of $100.1 million, G&A expenses of $18.6 million, and a net loss of $106.2 million. The filing explicitly states this is a disclosure of "Results of Operations and Financial Condition" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosing material financial results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces second quarter revenue of $14.5 million (120% YoY growth), gross margin of 59%, and raises full-year 2026 revenue guidance to $62–66 million. The press release (Exhibit 99.1) contains detailed financial statements, operational highlights, and forward-looking guidance, which are hallmarks of an earnings announcement. Material to investors as it reflects strong commercial momentum and improved financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-06
EX-99.1
This exhibit is a press release announcing Hepsiburada's unaudited financial results for Q2 2026 and H1 2026, dated August 6, 2026. It discloses key metrics including GMV, revenue, orders, EBITDA, and net loss, along with detailed financial tables and management commentary. Although the filing includes a restatement pursuant to IAS 29 (hyperinflation accounting), the primary disclosure is the quarterly earnings announcement, which is a material event affecting investor assessment of the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-08-06
Item 2.02
The Item 2.02 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with detailed metrics including cash position ($20.1M), R&D expenses ($7.4M), G&A expenses ($2.6M), asset impairment charges ($5.1M), and net loss ($14.9M). However, the press release is dominated by the announcement of a proposed merger with Avere Therapeutics and related restructuring activities, which materially overshadows the routine quarterly results disclosure. While this is technically an earnings release, the merger announcement (an M&A activity) is the primary material event driving the filing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Willdan issued a press release on August 6, 2026 announcing financial results for the second quarter ended July 3, 2026, with contract revenue of $231.0 million (up 33.2%), net income of $24.3 million (up 57.7%), and GAAP diluted EPS of $1.58 (up 53.4%). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The company also raised FY2026 financial targets, indicating material performance updates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Clean Energy Fuels Corp. issued a press release on August 6, 2026, announcing financial results for Q2 2026 ended June 30, 2026. The disclosure includes revenue of $106.4 million, net loss of $(14.9) million, and Adjusted EBITDA of $16.0 million, along with operational metrics such as RNG gallons sold (63.2 million). This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
ESCO Technologies disclosed its fiscal 2026 third quarter financial and operating results on August 6, 2026, reporting Q3 2026 sales of $339 million (14% increase), GAAP EPS from continuing operations of $1.26 (31% increase), and Adjusted EPS of $2.20 (38% increase), along with updated full-year FY 2026 guidance raising both sales and Adjusted EPS expectations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses financial results including R&D expenses ($5.1M vs $11.5M YoY), G&A expenses ($2.6M vs $2.5M YoY), net loss ($3.9M or $0.04 per share vs $6.7M or $0.11 per share YoY), and balance sheet data as of June 30, 2026. The filing includes unaudited selected financial data in tabular form and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release dated August 6, 2026 announcing CytoSorbents' financial results for the quarter ended June 30, 2026. The press release provides detailed Q2 2026 financial metrics including revenue ($9.6M), gross margin (73%), operating loss ($2.6M), net loss ($4.4M), and adjusted EBITDA loss ($1.6M), along with business highlights and regulatory updates. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
The 8-K discloses Global Net Lease's second quarter 2026 financial results through Item 7.01 (Regulation FD Disclosure), with a furnished earnings call transcript. The filing reports Q2 2026 revenue of $112.5 million, AFFO of $0.22 per share, and updated full-year 2026 guidance (AFFO per share raised to $0.82–$0.85 range, transaction volume guidance increased to $700–$800 million). This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The press release (Exhibit 99.1) discloses comprehensive financial results including sales of $56.2 million, net income of $4.7 million ($0.12 per diluted share), adjusted EBITDA of $7.6 million, and full-year 2026 guidance. The filing is made under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures, and includes both GAAP and non-GAAP measures with reconciliations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Monster Beverage Corporation issued a press release on August 6, 2026, disclosing financial results for the second quarter ended June 30, 2026, with net sales of $2.54 billion (up 20.2%), net income of $584.5 million (up 19.6%), and diluted EPS of $0.59 (up 19.0%), along with detailed segment performance and six-month results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 8.01
The filing announces the scheduled release of United States Antimony Corporation's Second Quarter 2026 Financial and Operating Results on August 11, 2026, at 4:15 p.m. ET, with a conference call and webcast. This is a standard earnings announcement that would materially affect investor assessment of the company's financial performance and operational results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The filing discloses total revenue of $40.1 million (vs. $2.1 million in Q2 2025), net product revenue of $25.1 million from AVMAPKI FAKZYNJA CO-PACK, and a net loss of $34.7 million. The press release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for results of operations and financial condition. Material to investors as it shows significant revenue growth from the newly commercialized product and cash position updates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Cryoport's Q2 2026 financial results. The Item 2.02 filing announces quarterly revenue of $49.0 million (8% YoY growth), gross margins, operating costs, and adjusted EBITDA of $0.4 million—a key milestone toward profitability. The press release is attached as Exhibit 99.1 and includes detailed financial tables, segment performance, and operational highlights, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
DoubleVerify issued a press release on August 6, 2026 announcing financial results for Q2 and H1 2026, including revenue of $193.8 million (up 3% YoY), net income of $12.9 million, and adjusted EBITDA of $65.3 million. The Item 2.02 disclosure and attached Exhibit 99.1 press release are the standard format for earnings announcements. While the filing also mentions a pending merger with Nielsen, the primary disclosure under Item 2.02 is the quarterly financial results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
The filing discloses Avient's second quarter 2026 financial results via a press release dated August 6, 2026. The press release reports Q2 2026 GAAP EPS of $0.70 (vs. $0.57 prior year), adjusted EPS of $0.96 (20% growth), sales growth of 5.8% to $917 million, and increased full-year 2026 adjusted EPS guidance to $3.10–$3.25 (10–15% growth). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and forward guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
nLIGHT announced its financial results for Q2 2026 on August 6, 2026, disclosing record revenues of $82.6 million (up 34% YoY), gross margin of 31.1%, and Adjusted EBITDA of $10.7 million. The full press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states this is the announcement of financial results for the three and six months ended June 30, 2026. This is a standard quarterly earnings release with detailed financial statements and forward guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses total company revenues of $425.5 million, product-specific revenues (BRINSUPRI $309.2M, ARIKAYCE $116.3M), operating expenses, net loss of $13.2 million, and balance sheet information. The company also raised full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.40 billion and raised peak revenue estimates for its three lead programs to more than $14 billion combined. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-06
EX-99.3
GH Research reported second quarter 2026 financial results, including a net loss of $15.1 million, cash position of $362.7 million, and detailed R&D and G&A expenses, along with condensed consolidated interim financial statements.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-06
EX-99.3
This exhibit is a press release announcing InflaRx's second quarter 2026 financial results, including unaudited consolidated statements of operations, financial position, changes in shareholders' equity, and cash flows for the six months ended June 30, 2026. The document explicitly states "InflaRx Reports Second Quarter 2026 Results" and includes detailed financial highlights, net loss figures (€16.2 million for H1 2026), and cash position (€158.4 million). This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a press release dated August 5, 2026, reporting Tronox's financial results for the second quarter ended June 30, 2026, attached as Exhibit 99.1 to the 8-K Item 2.02 filing. The disclosure includes detailed financial highlights (revenue of $868 million, net loss of $171 million, adjusted EBITDA of $73 million), segment performance, balance sheet metrics, and forward guidance for Q3 2026. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial condition and performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
SIGA Technologies issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, income statement), revenue figures ($37.9M product sales in Q2 2026), net income ($12.5M), and diluted EPS ($0.17), along with operational highlights regarding TPOXX product deliveries. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-06
EX-99.1
This exhibit is a press release announcing Seanergy's second quarter and first-half 2026 financial results, including record Q2 net income of $26.2 million and adjusted EPS of $1.32. The document presents comprehensive financial tables, reconciliations of non-GAAP measures, and management commentary on operational performance. While the release also discusses capital allocation (dividends, fleet renewal, and debt issuance), the primary disclosure is the quarterly and interim financial results, which is the hallmark of an earnings_release.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
SUI Group Holdings issued a press release on August 6, 2026, announcing its financial results for the fiscal second quarter ended June 30, 2026. The disclosure includes Q2 2026 financial summary with total revenue, net loss, and treasury updates, along with operational highlights. This is a standard earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's financial performance and digital asset treasury strategy.
View raw filing on EDGAR →